Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of July 7, 2025 • 5:30 AM ET

Date/Time Source News Release
07/02/2025 04:15 PM EDT GlobeNewswire Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
07/01/2025 09:25 AM EDT GlobeNewswire Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
06/30/2025 11:02 AM EDT Canada Newswire Oncology Innovation Just Hit a Turning Point -- Here's What to Watch
06/26/2025 08:05 AM EDT GlobeNewswire Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
06/24/2025 08:30 AM EDT GlobeNewswire Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
06/11/2025 08:05 AM EDT GlobeNewswire Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
06/05/2025 09:00 AM EDT GlobeNewswire Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
06/04/2025 08:05 AM EDT GlobeNewswire Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
05/13/2025 07:05 AM EDT GlobeNewswire Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
05/07/2025 08:05 AM EDT GlobeNewswire Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
Page